GSK Investigational Site

Oak Brook, Illinois 60532

0 studies enrolling now · 13 studies all time

What they study most

Asthma, COVID-19, Depressive Disorder, Depressive Disorder, Major, Diabetes Mellitus, Type 2, Epilepsy, HIV Infections, Infections, Meningococcal, Major Depressive Disorder (MDD), Restless Legs Syndrome, Restless Legs Syndrome (RLS), SARS-CoV-2

Studies at this site

• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults — Running, not enrolling
• Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants — Completed
• Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults — Completed
• Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) — Completed
• Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive — Completed
• Seasonal Affective Depression (SAD) Study — Completed
• Lethargic Depression Study — Completed
• Sexual Functioning Study With Antidepressants — Completed
• Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only — Completed
• Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome — Completed
• Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia — Completed
• GSK BHR Study (Sont - Second Study) — Completed
• Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia — Completed